Processing your payment...
Please do not close your browser.

Vaccine Market Growth and Forecast (2022-2029) By Technology (Inactivated & Subunit vaccines, Viral vector vaccines) By Route of Administration (Intramuscular administration, Oral administration) and By Regions

12 Jul, 2022 | 156 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the forecast period, the Vaccine Market will register a CAGR of 10 % in terms of revenue and the global market size will reach USD 69 Billion by 2029.

Vaccine Market Overview

The potential for new infectious illnesses to spread quickly and produce worldwide epidemics is a serious issue due to people's increased exposure to wild animals, increased frequency and distance of travel, and increased living conditions. In addition, there is a chance that illnesses might spread due to their intentional introduction into populations of people, animals, or plants for terrorist goals. About 40 infectious illnesses, including SARS, MERS, Ebola, chikungunya, avian flu, swine flu, Zika, and most recently COVID-19, have been identified. Future pandemics and outbreaks might be even deadlier than COVID-19, experts have warned.

Due to their rising patient populations and disposable incomes, emerging regions like China, India, and Southeast Asia present expanding the potential for the vaccination business. Major market firms have been enticed to invest in these economies by their development potential. Additionally, businesses are putting money into and concentrating on creating inexpensive vaccinations to expand the reach of immunization programs in these economies.

What is our Vaccine Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029

 

CAGR of 10 % during the review period (2022 to 2029).

 

By Technology

  • Conjugate vaccines
  • Inactivated & Subunit vaccines
  • Live Attenuated vaccines
  • Recombinant vaccines
  • Toxoid vaccines
  • Viral vector vaccines

 

By Route of Administration

 

 

 

 

  • Intramuscular & Subcutaneous administration
  • Oral administration
  • Other routes of administration (intranasal, intradermal, and percutaneous)

By End-User

  • Pediatric vaccines
  • Adult vaccines

 

 

 

By Companies

  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi SA
  • CSL Limited
  • Emergent BioSolutions Inc.
  • Johnson & Johnson
  • AstraZeneca plc
  • Serum Institute of India Pvt. Ltd.
  • Bavarian Nordic A/S
  • Mitsubishi Tanabe Pharma Corporation
  • Daiichi Sankyo Company Limited
  • Panacea Biotec Ltd.
  • Biological E Limited
  • Bharat Biotech Ltd.
  • Novavax Inc. (US)
  • FSUE NPO Microgen
  • Sinovac BiotechLtd.
  • Incepta Vaccine Limited
  • Valneva SE
  • VBI Vaccines
  • PT Bio Farma (Persero)
  • Inovio Pharmaceuticals Inc.
  • Chongqing Zhifei Biological Products Co. Ltd.
  • Indian Immunologicals Limited

 

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

Base Year

2022

 

Historical Year

 

 

2017 to 2021

Forecast Year

 

2022 to 2029

Number of Pages

156

 

Customization Available

 

 

Yes, the report can be customized as per your needs

Frequently Asked Questions

What is the current Market size and compound annual growth rate (CAGR) of the Vaccine Market during the forecast period (2022-2029)?

The Vaccine Market is growing at a CAGR of 10 % over the next 7 years.

Who are the key players in Vaccine Market?

GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi SA (France), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), AstraZeneca plc (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic A/S (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec, Ltd. (India), Biological E Limited (India), Bharat Biotech Ltd. (India), Novavax, Inc. (US), FSUE NPO Microgen (Russia), Sinovac Biotech, Ltd. (China), Incepta Vaccine Limited (Bangladesh), Valneva SE (France), VBI Vaccines (US), PT Bio Farma (Persero) (Indonesia), Inovio Pharmaceuticals, Inc. (US), Chongqing Zhifei Biological Products Co., Ltd. (China), and Indian Immunologicals Limited (India), Others.

What region does this Vaccine Market report covers?

North America (the United States, Canada, and Mexico), Europe (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, Colombia, etc.), The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

What are the significant Technology of Vaccine Market?

Conjugate vaccines, Inactivated & Subunit vaccines, Live Attenuated vaccines, Recombinant vaccines, Toxoid vaccines, Viral vector vaccines.

What are the significant Route of Administration of Vaccine Market?

Intramuscular & Subcutaneous administration, Oral administration, Other routes of administration (intranasal, intradermal, and percutaneous).

Who are the Major Players in Vaccine Market?

Market Growth Reports lists out all the Vaccine Market companies that are presently striving to reduce the impact of the Covid-19 pandemic on the Market- GlaxoSmithKline plc (UK), Merck & Co. Inc., Pfizer, Inc., Sanofi SA, CSL Limited, Emergent BioSolutions Inc., Johnson & Johnson (US), AstraZeneca plc, Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Panacea Biotec, Ltd., Biological E Limited, Bharat Biotech Ltd., Novavax, Inc., FSUE NPO Microgen, Sinovac Biotech, Ltd., Incepta Vaccine Limited, Valneva SE, VBI Vaccines, PT Bio Farma, Inovio Pharmaceuticals Inc., Chongqing Zhifei Biological Products Co. Ltd., and Indian Immunologicals Limited, Others.

Industry News:

In October 2021, The Pfizer-BioNTech COVID-19 vaccine for children aged 5 to 11 has been granted emergency use authorization (EUA) by the US Food and Drug Administration (US FDA).

In July 2021, Shingrix (Zoster Vaccine Recombinant, Adjuvanted) from GSK has been given US FDA approval for persons 18 years of age and older who are or will be at elevated risk of developing shingles owing to immunosuppression brought on by a known illness or treatment.

What are the major technologies, Routes of Administration, and End Users for the Vaccine Market?

By Technology, it is segmented into

  • Conjugate vaccines
  • Inactivated & Subunit vaccines
  • Live Attenuated vaccines
  • Recombinant vaccines
  • Toxoid vaccines
  • Viral vector vaccines

By Route of Administration, it is segmented into

  • Intramuscular & Subcutaneous administration
  • Oral administration
  • Other routes of administration (intranasal, intradermal, and percutaneous)

By End User, it is segmented into

  • Pediatric vaccines
  • Adult vaccines

Vaccine Market Regional Analysis

The largest geographic market for vaccines in 2020 was in North America. The market is essentially divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa based on region. North America held the highest share of the market in 2020. The market in North America is driven by factors including required reporting and the rising occurrence of infectious illnesses.

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America
  1. INTRODUCTION
    1. MARKET DEFINITION
    2. MARKET DYNAMICS
    3. MARKET SEGMENTATION
    4. REPORT TIMELINES
    5. KEY STAKEHOLDERS
  2. RESEARCH METHODOLOGY
    1. DATA MINING
      1. SECONDARY RESEARCH
      2. PRIMARY RESEARCH
      3. SUBJECT MATTER EXPERT ADVICE
    2. QUALITY CHECK
    3. FINAL REVIEW
      1. DATA TRIANGULATION
      2. BOTTOM-UP APPROACH
      3. TOP-DOWN APPROACH
      4. RESEARCH FLOW
  3. EXECUTIVE SUMMARY
    1. INTRODUCTION
    2. GLOBAL VACCINE MARKET BY TECHNOLOGY
    3. GLOBAL VACCINE MARKET BY ROUTE OF ADMINISTRATION
    4. GLOBAL VACCINE MARKET, BY END-USER
  4. MARKET DYNAMICS
    1. DRIVERS
      1. INCREASING DEMAND FOR MSM SUPPLEMENT
    2. RESTRAINTS
      1. STRINGENT ENVIRONMENTAL REGULATIONS
      2. HIGH COST OF MATERIALS
    3. OPPORTUNITIES
      1. VACCINE MARKET GROWTH
    4. APPLICATION OF VACCINE MARKET IMPACT OF COVID 19
  5. GLOBAL VACCINE MARKET, BY TECHNOLOGY
    1. INTRODUCTION
    2. CONJUGATE VACCINES
    3. INACTIVATED & SUBUNIT VACCINES
    4. LIVE ATTENUATED VACCINES
    5. RECOMBINANT VACCINES
    6. TOXOID VACCINES
    7. VIRAL VECTOR VACCINES
  6. GLOBAL VACCINE MARKET, BY ROUTE OF ADMINISTRATION
    1. INTRODUCTION
    2. INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
    3. ORAL ADMINISTRATION
    4. OTHER ROUTES OF ADMINISTRATION (INTRANASAL, INTRADERMAL, AND PERCUTANEOUS)
  7. GLOBAL VACCINE MARKET, BY END-USER
    1. INTRODUCTION
    2. PEDIATRIC VACCINES
    3. ADULT VACCINES
  8. GLOBAL VACCINE MARKET, BY REGION
    1. NORTH AMERICA
      1. US
      2. CANADA
      3. MEXICO
    2. EUROPE
      1. GERMANY
      2. FRANCE
      3. UK
      4. ITALY
      5. RUSSIA
      6. REST OF EUROPE
    3. APAC
      1. CHINA
      2. SOUTH KOREA
      3. JAPAN
      4. INDIA
      5. AUSTRALIA
      6. ASEAN
      7. REST OF APAC
    4. MIDDLE EAST AND AFRICA
      1. SAUDI ARABIA
      2. UAE
      3. SOUTH AFRICA
      4. TURKEY
      5. REST OF MEA
    5. SOUTH AMERICA
      1. BRAZIL
      2. REST OF MEA
      3. ARGENTINA
      4. REST OF SOUTH AMERICA
  9. COMPETITIVE LANDSCAPE
    1. MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
    2. AND AGREEMENTS
      1. KEY DEVELOPMENT
    3. MARKET SHARE PERCENT/RANKING ANALYSIS
    4. STRATEGIES ADOPTED BY LEADING PLAYERS
  10. COMPANY PROFILES
    1. BUSINESS OVERVIEW
    2. COMPANY SNAPSHOT
    3. PRODUCT BENCHMARKING
    4. STRATEGIC INITIATIVES
    5. MERCK & CO. INC.
    6. PFIZER INC.
    7. SANOFI SA
    8. CSL LIMITED
    9. EMERGENT BIOSOLUTIONS INC.
    10. JOHNSON & JOHNSON
    11. ASTRAZENECA PLC
    12. SERUM INSTITUTE OF INDIA PVT. LTD.
    13. BAVARIAN NORDIC A/S
    14. MITSUBISHI TANABE PHARMA CORPORATION
    15. DAIICHI SANKYO COMPANY LIMITED
    16. PANACEA BIOTEC LTD.
    17. BIOLOGICAL E LIMITED
    18. BHARAT BIOTECH LTD.
    19. NOVAVAX INC. (US)
    20. FSUE NPO MICROGEN
    21. SINOVAC BIOTECHLTD.
    22. INCEPTA VACCINE LIMITED
    23. VALNEVA SE
    24. VBI VACCINES
    25. PT BIO FARMA (PERSERO)
    26. INOVIO PHARMACEUTICALS INC.
    27. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO. LTD.
    28. INDIAN IMMUNOLOGICALS LIMITED

 

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla